21 – 30 of 185
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2023
-
Mark
Antibodies against Porphyromonas gingivalis in serum and saliva and their association with rheumatoid arthritis and periodontitis. Data from two rheumatoid arthritis cohorts in Sweden
(
- Contribution to journal › Article
-
Mark
Certolizumab pegol, abatacept, tocilizumab or active conventional treatment in early rheumatoid arthritis : 48-week clinical and radiographic results of the investigator-initiated randomised controlled NORD-STAR trial
(
- Contribution to journal › Article
-
Mark
Developing a complex vocational rehabilitation intervention for patients with inflammatory arthritis : the WORK-ON study
(
- Contribution to journal › Article
- 2022
-
Mark
Health-Care and Societal Costs Associated with Non-Persistence with Subcutaneous TNF-α Inhibitors in the Treatment of Inflammatory Arthritis (IA) : A Retrospective Observational Study
(
- Contribution to journal › Article
-
Mark
Association of autoimmune diseases with cardiomyopathy : A nationwide follow-up study from Sweden
(
- Contribution to journal › Article
-
Mark
Erosion-free rheumatoid arthritis : clinical and conceptional implications—a BARFOT study
(
- Contribution to journal › Article
-
Mark
Autoimmune disease – phenotypic alterations of peripheral immune cells and clinical correlates
2022) In Lund University, Faculty of Medicine Doctoral Dissertation Series(
- Thesis › Doctoral thesis (compilation)
-
Mark
Galectin-3 Decreases 4-1BBL Bioactivity by Crosslinking Soluble and Membrane Expressed 4-1BB
(
- Contribution to journal › Article
-
Mark
Smoking Cessation Rates among Patients with Rheumatoid Arthritis and Osteoarthritis Following the 'Gold Standard Programme' (GSP): : A Prospective Analysis from the Danish Smoking Cessation Database
(
- Contribution to journal › Article
-
Mark
Short-term, intermediate-term and long-term risks of acute coronary syndrome in cohorts of patients with RA starting biologic DMARDs : Results from four Nordic countries
(
- Contribution to journal › Article